An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe

Chloe Orkin, Jianmin Wang, Colm Bergin, Jean Michel Molina, Adriano Lazzarin, Matthias Cavassini, Stefan Esser, Juan Luis Gómez Sirvent, Helen Pearce

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVES: HLA-B*5701 is a major histocompatibility complex class I allele associated with an immunologically-mediated hypersensitivity reaction to abacavir. The objectives of this study were to evaluate HLA-B*5701 prevalence among European, HIV-1-infected patients and to compare the local and central laboratory screening results. METHODS: Data were combined from six multicentre, prospective studies involving 10 European countries in which HIV-1-infected patients (irrespective of treatment experience or previous HLA-B*5701 screening), ≥ 18 years of age, were evaluated for HLA-B*5701 carriage, determined by the central and local laboratory methods. RESULTS: A total of 9720 patients from 272 centres were included in the analysis. The overall estimate of HLA-B*5701 prevalence in Europe was 4.98%, with country-specific estimates ranging from 1.53 to 7.75%. HLA-B*5701 prevalence was highest in the self-reported white population (6.49%) and lowest in the black population (0.39%). Local laboratory results had a high specificity (99.9%) and sensitivity (99.2%) when compared with the central laboratory results. CONCLUSION: This study supports data from previous studies regarding the prevalence of HLA-B*5701 in the HIV population and the variation of HLA-B*5701 prevalence between different racial groups. The high specificity and sensitivity of local laboratory results, suggests that clinicians can be confident in using local laboratories for pretreatment HLA-B*5701 screening. However, it is essential that local laboratories participate in HLA-B*5701-specific quality assurance programs to maintain 100% sensitivity. In HIV-infected patients, pretreatment HLA-B*5701 screening may allow more informed decisions regarding abacavir use and has the potential to significantly reduce the frequency of abacavir-related hypersensitivity reactions and costs associated with managing these reactions.

Original languageEnglish
Pages (from-to)307-314
Number of pages8
JournalPharmacogenetics and Genomics
Volume20
Issue number5
DOIs
Publication statusPublished - May 2010

Fingerprint

HLA-B Antigens
Epidemiologic Studies
Alleles
HIV
HIV-1
Hypersensitivity
Population
Sensitivity and Specificity
Major Histocompatibility Complex
Multicenter Studies
Cross-Sectional Studies
Prospective Studies

Keywords

  • Abacavir
  • Histocompatibility complex class I
  • HLA-B 5701
  • Hypersensitivity
  • Pretreatment screening
  • Prevalence

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe. / Orkin, Chloe; Wang, Jianmin; Bergin, Colm; Molina, Jean Michel; Lazzarin, Adriano; Cavassini, Matthias; Esser, Stefan; Gómez Sirvent, Juan Luis; Pearce, Helen.

In: Pharmacogenetics and Genomics, Vol. 20, No. 5, 05.2010, p. 307-314.

Research output: Contribution to journalArticle

Orkin, C, Wang, J, Bergin, C, Molina, JM, Lazzarin, A, Cavassini, M, Esser, S, Gómez Sirvent, JL & Pearce, H 2010, 'An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe', Pharmacogenetics and Genomics, vol. 20, no. 5, pp. 307-314. https://doi.org/10.1097/FPC.0b013e3283390666
Orkin, Chloe ; Wang, Jianmin ; Bergin, Colm ; Molina, Jean Michel ; Lazzarin, Adriano ; Cavassini, Matthias ; Esser, Stefan ; Gómez Sirvent, Juan Luis ; Pearce, Helen. / An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe. In: Pharmacogenetics and Genomics. 2010 ; Vol. 20, No. 5. pp. 307-314.
@article{350499a0d1d54b0e99d1bae0033c8cf0,
title = "An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe",
abstract = "OBJECTIVES: HLA-B*5701 is a major histocompatibility complex class I allele associated with an immunologically-mediated hypersensitivity reaction to abacavir. The objectives of this study were to evaluate HLA-B*5701 prevalence among European, HIV-1-infected patients and to compare the local and central laboratory screening results. METHODS: Data were combined from six multicentre, prospective studies involving 10 European countries in which HIV-1-infected patients (irrespective of treatment experience or previous HLA-B*5701 screening), ≥ 18 years of age, were evaluated for HLA-B*5701 carriage, determined by the central and local laboratory methods. RESULTS: A total of 9720 patients from 272 centres were included in the analysis. The overall estimate of HLA-B*5701 prevalence in Europe was 4.98{\%}, with country-specific estimates ranging from 1.53 to 7.75{\%}. HLA-B*5701 prevalence was highest in the self-reported white population (6.49{\%}) and lowest in the black population (0.39{\%}). Local laboratory results had a high specificity (99.9{\%}) and sensitivity (99.2{\%}) when compared with the central laboratory results. CONCLUSION: This study supports data from previous studies regarding the prevalence of HLA-B*5701 in the HIV population and the variation of HLA-B*5701 prevalence between different racial groups. The high specificity and sensitivity of local laboratory results, suggests that clinicians can be confident in using local laboratories for pretreatment HLA-B*5701 screening. However, it is essential that local laboratories participate in HLA-B*5701-specific quality assurance programs to maintain 100{\%} sensitivity. In HIV-infected patients, pretreatment HLA-B*5701 screening may allow more informed decisions regarding abacavir use and has the potential to significantly reduce the frequency of abacavir-related hypersensitivity reactions and costs associated with managing these reactions.",
keywords = "Abacavir, Histocompatibility complex class I, HLA-B 5701, Hypersensitivity, Pretreatment screening, Prevalence",
author = "Chloe Orkin and Jianmin Wang and Colm Bergin and Molina, {Jean Michel} and Adriano Lazzarin and Matthias Cavassini and Stefan Esser and {G{\'o}mez Sirvent}, {Juan Luis} and Helen Pearce",
year = "2010",
month = "5",
doi = "10.1097/FPC.0b013e3283390666",
language = "English",
volume = "20",
pages = "307--314",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe

AU - Orkin, Chloe

AU - Wang, Jianmin

AU - Bergin, Colm

AU - Molina, Jean Michel

AU - Lazzarin, Adriano

AU - Cavassini, Matthias

AU - Esser, Stefan

AU - Gómez Sirvent, Juan Luis

AU - Pearce, Helen

PY - 2010/5

Y1 - 2010/5

N2 - OBJECTIVES: HLA-B*5701 is a major histocompatibility complex class I allele associated with an immunologically-mediated hypersensitivity reaction to abacavir. The objectives of this study were to evaluate HLA-B*5701 prevalence among European, HIV-1-infected patients and to compare the local and central laboratory screening results. METHODS: Data were combined from six multicentre, prospective studies involving 10 European countries in which HIV-1-infected patients (irrespective of treatment experience or previous HLA-B*5701 screening), ≥ 18 years of age, were evaluated for HLA-B*5701 carriage, determined by the central and local laboratory methods. RESULTS: A total of 9720 patients from 272 centres were included in the analysis. The overall estimate of HLA-B*5701 prevalence in Europe was 4.98%, with country-specific estimates ranging from 1.53 to 7.75%. HLA-B*5701 prevalence was highest in the self-reported white population (6.49%) and lowest in the black population (0.39%). Local laboratory results had a high specificity (99.9%) and sensitivity (99.2%) when compared with the central laboratory results. CONCLUSION: This study supports data from previous studies regarding the prevalence of HLA-B*5701 in the HIV population and the variation of HLA-B*5701 prevalence between different racial groups. The high specificity and sensitivity of local laboratory results, suggests that clinicians can be confident in using local laboratories for pretreatment HLA-B*5701 screening. However, it is essential that local laboratories participate in HLA-B*5701-specific quality assurance programs to maintain 100% sensitivity. In HIV-infected patients, pretreatment HLA-B*5701 screening may allow more informed decisions regarding abacavir use and has the potential to significantly reduce the frequency of abacavir-related hypersensitivity reactions and costs associated with managing these reactions.

AB - OBJECTIVES: HLA-B*5701 is a major histocompatibility complex class I allele associated with an immunologically-mediated hypersensitivity reaction to abacavir. The objectives of this study were to evaluate HLA-B*5701 prevalence among European, HIV-1-infected patients and to compare the local and central laboratory screening results. METHODS: Data were combined from six multicentre, prospective studies involving 10 European countries in which HIV-1-infected patients (irrespective of treatment experience or previous HLA-B*5701 screening), ≥ 18 years of age, were evaluated for HLA-B*5701 carriage, determined by the central and local laboratory methods. RESULTS: A total of 9720 patients from 272 centres were included in the analysis. The overall estimate of HLA-B*5701 prevalence in Europe was 4.98%, with country-specific estimates ranging from 1.53 to 7.75%. HLA-B*5701 prevalence was highest in the self-reported white population (6.49%) and lowest in the black population (0.39%). Local laboratory results had a high specificity (99.9%) and sensitivity (99.2%) when compared with the central laboratory results. CONCLUSION: This study supports data from previous studies regarding the prevalence of HLA-B*5701 in the HIV population and the variation of HLA-B*5701 prevalence between different racial groups. The high specificity and sensitivity of local laboratory results, suggests that clinicians can be confident in using local laboratories for pretreatment HLA-B*5701 screening. However, it is essential that local laboratories participate in HLA-B*5701-specific quality assurance programs to maintain 100% sensitivity. In HIV-infected patients, pretreatment HLA-B*5701 screening may allow more informed decisions regarding abacavir use and has the potential to significantly reduce the frequency of abacavir-related hypersensitivity reactions and costs associated with managing these reactions.

KW - Abacavir

KW - Histocompatibility complex class I

KW - HLA-B 5701

KW - Hypersensitivity

KW - Pretreatment screening

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=77951621770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951621770&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e3283390666

DO - 10.1097/FPC.0b013e3283390666

M3 - Article

C2 - 20375757

AN - SCOPUS:77951621770

VL - 20

SP - 307

EP - 314

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 5

ER -